Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
Preface
Sawan M. et al, (2025), Proceedings of 2024 3rd International Conference on Public Health and Data Science, ICPHDS 2024
2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations II: diagnostic tests and prediction models.
Di Angelantonio E. et al, (2025), Eur Heart J
2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention.
Jüni P. et al, (2025), Eur Heart J
Balancing the risk of major bleeding against vascular disease risk in people without atherosclerotic disease.
Hammami I. et al, (2025), Heart
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787
Accuracy of healthcare systems data for identifying cardiovascular outcomes after stroke due to intracerebral haemorrhage in the United Kingdom.
Hosking A. et al, (2024), Trials, 25
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK. et al, (2024), Nephrol Dial Transplant
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study.
Mihaylova B. et al, (2024), Lancet Reg Health Eur, 40
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial.
Petrucci G. et al, (2024), Eur Heart J, 45, 1355 - 1367
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.
Wu R. et al, (2024), Br J Gen Pract, 74, e189 - e198
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
Mayne KJ. et al, (2024), J Am Soc Nephrol, 35, 202 - 215
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 51 - 60
Thromboxane biosynthesis and risk of future events in diabetes mellitus: A sub-study of the ASCEND trial.
PARISH S. et al, (2023), European Heart Journal
Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.
Baigent C. and Sádaba R., (2023), Eur Heart J
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP).
Herrington WG. et al, (2023), Kidney Int Rep, 8, 1489 - 1495